Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

被引:9
作者
Rizzoli, Rene [1 ,2 ]
机构
[1] Univ Hosp, Dept Rehabil & Geriatr, Div Bone Dis, CH-1211 Geneva, Switzerland
[2] Fac Med Geneva, Dept Rehabil & Geriatr, Div Bone Dis, CH-1211 Geneva, Switzerland
关键词
bone mineral density; glucocorticoid-induced osteoporosis; hip fractures; osteopenia; osteoporosis; postmenopausal; zoledronic acid;
D O I
10.1177/1759720X09352920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is increasing interest in therapies that can be administered less frequently and/or avoid gastrointestinal irritation. The efficacy of once-yearly zoledronic acid (5 mg) in the treatment and prevention of osteoporosis has been evaluated in different patient populations. In the 3-year HORIZON-Pivotal Fracture Trial in postmenopausal women with osteoporosis, zoledronic acid reduced the risk of vertebral and hip fracture by 70% and 41%, respectively, versus placebo. The efficacy of zoledronic acid in preventing subsequent fracture in patients with a hip fracture was evaluated in the HORIZON-Recurrent Fracture Trial. New vertebral and nonvertebral fractures were significantly reduced by treatment initiated within 90 days of incident hip fracture, without evidence of delayed fracture healing. Data from a 1-year study show that a single zoledronic acid 5-mg infusion is superior to oral risedronate 5 mg/day for treatment and prevention of glucocorticoid-induced osteoporosis. Increases in bone mineral density and decreases in bone turnover markers were significantly greater with zoledronic acid than with risedronate. Two different treatment regimens of zoledronic acid were found to be more effective than placebo for prevention of bone loss in postmenopausal women and reducing markers of bone turnover after 2 years. In conclusion, zoledronic acid 5mg once-yearly infusion has demonstrated marked efficacy in the treatment and prevention of primary and secondary osteoporosis, with a combination of fracture risk reduction and prevention of bone loss at key sites. It is the only agent shown to reduce the incidence of fracture and mortality in patients with a previous low-trauma hip fracture.
引用
收藏
页码:3 / 16
页数:14
相关论文
共 50 条
[31]   Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis [J].
Ringe, Johann D. .
PATIENT PREFERENCE AND ADHERENCE, 2010, 4 :231-245
[32]   Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect [J].
Lewiecki, E. Michael .
CORE EVIDENCE, 2009, 4 :13-23
[33]   Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy [J].
Hines, Stephanie L. ;
Sloan, Jeff A. ;
Atherton, Pamela J. ;
Perez, Edith A. ;
Dakhil, Shaker R. ;
Johnson, David B. ;
Reddy, Pavan S. ;
Dalton, Robert J. ;
Mattar, Bassam I. ;
Loprinzi, Charles L. .
BREAST, 2010, 19 (02) :92-96
[34]   A Clinician's Perspective on the Use of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis [J].
Lewiecki, E. Michael .
JOURNAL OF CLINICAL DENSITOMETRY, 2008, 11 (04) :478-484
[35]   Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation [J].
Anna Spångeus ;
Simon Johansson ;
Mischa Woisetschläger .
Archives of Osteoporosis, 2020, 15
[36]   The role of zoledronic acid in the management of osteoporosis [J].
Maricic, Michael .
CLINICAL RHEUMATOLOGY, 2010, 29 (10) :1079-1084
[37]   Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis [J].
Kong, Li ;
Zuo, Kai ;
Ma, Long .
PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2020, 36 (07) :1703-1707
[38]   Comparative Efficacy of Vitamin D Supplementation and Zoledronic Acid Injection in Osteoporosis Treatment: A Clinical Study [J].
Zhou, Fulin ;
Wu, Hao ;
Yin, Zhen ;
Zhou, Weibo ;
Chen, Wei .
CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2024, 22 (01) :360-365
[39]   HEPATOTOXICITY INDUCED BY ZOLEDRONIC ACID IN AN AGED WOMAN WITH PRIMARY OSTEOPOROSIS [J].
Lu, Yanhui ;
Pei, Yu ;
Shao, Yinghong ;
Yan, Shuangtong ;
Ma, Lichao ;
Fang, Fusheng ;
Jin, Mengmeng ;
Liu, Minyan ;
Li, Jian ;
Li, Chunlin .
EXCLI JOURNAL, 2013, 12 :115-117
[40]   The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis [J].
Jawl-Shan Hwang ;
Lin-Show Chin ;
Jung-Fu Chen ;
Tzay-Shing Yang ;
Po-Quang Chen ;
Keh-Sung Tsai ;
Ping Chung Leung .
Journal of Bone and Mineral Metabolism, 2011, 29 :328-333